An Overview of Parkinson s Medication used in Multiple System Atrophy
|
|
- Primrose Curtis
- 5 years ago
- Views:
Transcription
1 Introduction The cause of Parkinson s symptoms The types of Parkinson s drugs used in MSA Finding the best medication Additional medication Drugs to avoid Further information An Overview of Parkinson s Medication used in Multiple System Atrophy Introduction This leaflet is for people with MSA, their carers and their family members. It provides information about the drugs most commonly used to help manage the condition and is aimed at increasing your understanding of the available drugs rather than prescribing what may be of benefit. Whilst there is no specific treatment for MSA, some of the symptoms may be managed by Parkinson s medications. They are not effective for everyone with MSA, but may be beneficial for some, particularly those who have Parkinson-type symptoms. We cannot advise on ideal combinations or provide details about the strengths or duration of action for each medication. Each person with MSA will respond differently to medication and you should discuss these issues with your Neurologist, Specialist or Parkinson s Nurse Specialist (PNS). The cause of Parkinson s symptoms The cause of Parkinson s is still unknown but it occurs due to a loss of nerve cells in the brain. The lost nerve cells are responsible for producing a chemical in the body called dopamine. Dopamine is a chemical that transmits messages to parts of the brain involved with the coordination of movement. The loss of the dopamine producing cells causes a lowering of dopamine in the body which causes a loss of control over bodily movement. A common treatment of the symptoms of Parkinson s is to increase the dopamine levels. The increased levels of dopamine allow greater control over bodily movement. Common Parkinson s medication attempt to increase the dopamine levels in different ways and it is these different ways that form the basic medication groups.
2 Types of Parkinson s drugs used in MSA Levodopa Levodopa is one of the main drugs used in the treatment of Parkinson s symptoms. Levodopa is a chemical building block that the body converts into dopamine, increasing the levels of dopamine in the brain. Levodopa can come in branded and unbranded forms. Other names for Levodopa include: Co-beneldopa (Madopar or Madopar CR) Co-careldopa, (Caramet CR, Sinemet, Sinemet Plus, Sinemet CR, Half Sinemet CR, Lecado) Co-careldopa plus entacapone (Stalevo) Levodopa can cause nausea and vomiting: Domperidone (Motilium) is the most common antisickness drug prescribed to prevent this. It is the only anti-sickness medication someone with MSA may take, others will make symptoms of MSA worse. Dopamine Agonists An agonist is a chemical that binds to a receptor and activates it to produce a biological response. Dopamine agonists are drugs that work by heightening the activity of dopamine receptors in the brain. This makes is easier for the brain to receive dopamine signals. In management of Parkinson s it s sometimes given in conjunction with Levodopa, the Levodopa increases the amount of dopamine and the agonist increases the ability to receive that dopamine. Dopamine agonists come in branded and unbranded forms. Common names for dopamine agonists include: Pramipexole (Mirapexin, Mirapexin prolonged release) Ropinirole (Adartrel, Ralnea XL, Requip, Requip XL, Rotigotine (Neupro) Neupro/Rotigotine Transdermal Patch A dopamine receptor agonist this may be used when swallowing is difficult or for the treatment of Restless Leg Syndrome. It is delivered via a patch that is placed on the skin every 72 hours. Monoamine Oxidase Type B (Mao-B) Inhibitors MAO-B is an enzyme that the body releases to break down any left over dopamine. This left over dopamine is there because the dopamine receptors only need so much in order to receive the brain signal. The excess dopamine is then destroyed and MAO-B inhibitors work by breaking down the MAO-B before it is able to destroy the dopamine, which increases the chance for a signal to be received. Again, in Parkinson s treatment it is common for them to be used in conjunction with other drug types. MAO-B Inhibitors come in generic and brand forms. They are commonly called: Rasagiline (Azilect) Selegiline (Eldepryl, Zelapar)
3 Glutamate Antagonist An antagonist blocks the action of a agonist. It isn t entirely clear how glutamate antagonists work but possibly they inhibit the action of glutamate receptors which increases dopamine release and blocks the re-uptake of dopamine. This will increase the likelihood of dopamine messages being transmitted through the brain. It is not prescribed very often in Parkinson s treatment and has only a mild impact on main symptoms, but can have a positive effect on tiredness and stiffness. The only glutamate antagonist drug used in Parkinson s treatment is called: Amantadine (Symmetrel) Finding the best medication MSA affects everyone differently. Because of this there is no correct dose or medication. Finding the best medication, dose and timing may take some time and will need some changes along the way. Because the symptoms of MSA can change over time, your medication will sometimes have to change, too. While you may be able to talk to your GP about any side effects of medication you experience, or speak to them about issues that aren t related to the condition, ideally, you should discuss Parkinson s medication with your Neurologist, Specialist, Parkinson s Nurse Specialist (PNS) or Pharmacist. It is important not to make any changes to your own medication without talking to your specialist or PNS first. You will be advised about timing of medication by your prescriber (one of the people mentioned above). It is beneficial to take any Parkinson s medication as close to the times given as possible. If you should develop any side effects from medication do discuss this with your specialist or PNS before stopping the medication. It can be dangerous to stop taking Parkinson s medication suddenly. Generally these medications should be reduced gradually with the advice and guidance of your PNS. Additional medication If you have other medical conditions, this may affect your Parkinson s symptoms and also how effective the Parkinson s drugs can be. Some medications for other conditions can make Parkinson s symptoms worse (see below). If you have a problem with your digestive system, such as constipation (which is a common symptom in MSA) this may affect how well your drugs enter your bloodstream and may reduce the effectiveness of the medication. Parkinson s drugs can interact with drugs used for other conditions. Herbal or complementary treatments may also impact on Parkinson s drugs. If you want to take a non-prescription medicine, check with your pharmacist first that it is safe. Anti-sickness, travel remedies, decongestants or cold remedies can affect some Parkinson s medications. If you need to use these, check with your pharmacist which one is safest to use.
4 Your Specialist, Parkinson s Nurse Specialist or pharmacist can give you advice on specific interactions with different medications. Drugs to avoid Some drugs can bring on Parkinson s-like symptoms or react badly with Parkinson s drugs and should be avoided unless they re recommended by a specialist. These are some (but not all) of the drugs to avoid in MSA: Metoclopramide (Maxalon) Prochlorperazine (Stemetil) Chlorpromazine (Largactil) Fluphenazine (Modecate) Fluphenazine with nortriptyline (Motival) Perphenazine (Fentazin/Triptafen) Trifluoperazine (Stelazine) Flupenthixol (Fluanxol/Depixol) Haloperidol (Serenace/Haldol) If you have any queries about medication, contact your Specialist, Parkinson s Nurse Specialist or pharmacist. Further information Parkinson s UK Website contains detailed information about Parkinson s drugs. W: The electronic Medicines Compendium (emc) Contains accessible information about medicines licensed in the UK and patient medicines guides. W: NHS Choices Medicines Information about medications and side effects and contains an online search facility for finding your local pharmacist. W:
5 Samantha Pavey: T: E: Katie Rigg T: E: Jill Lyons T: E: Emma Saunders T: E: REVISION DATE: 05/17 REVIEW DATE: 05/19 VERSION: 1.3 Disclaimer We have taken every care to ensure the accuracy of the information contained in this publication. It is produced independently, is not influenced by sponsors and is free from endorsement. The information should not be used as a substitute for the advice of appropriately qualified professionals, if in any doubt please seek advice from your doctor or legal professional. References for this information sheet are available by contacting support@msatrust.org.uk Feedback Your feedback helps us ensure we are delivering information to the highest standard. If you have any comments or suggestions please complete a short survey by following the links from our website: or by contacting us at support@msatrust.org.uk
An Overview of Parkinson s Medication used in Multiple System Atrophy
Introduction Cause of Parkinson s symptoms Parkinson s drug use in MSA Finding the best medication Other medication - Interaction Drugs to avoid Further information An Overview of Parkinson s Medication
More informationParkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust
n The Leeds Teaching Hospitals NHS Trust Parkinson s disease Information for patients and carers in partnership with Leeds Community Healthcare NHS Trust The symptoms of Parkinson s appear when the levels
More informationAppendix 2: Admissions checklists for people with Parkinson s
Appendix 2: Admissions checklists for people with Parkinson s This document is intended to form the basis of a locally developed tool and so it has been built to be amended with relevant local information,
More informationMANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW
MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW Author: Gordon W Duncan Status: Approved Authorised by: Clinical Policy Group Version: 1.0 Review date:
More informationGuidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth
Index No: MMG48 Guidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth Version: 2.0 Date ratified: November 2017 Ratified by: (Name of Committee) Name
More informationFatigue in MSA. Introduction. What is fatigue? Recognising fatigue
Introduction What is fatigue? Recognising fatigue What causes fatigue Managing fatigue Further support Fatigue in MSA Introduction We know that fatigue is a symptom that affects a lot of people living
More informationPARKINSON S MEDICATION
PARKINSON S MEDICATION History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development
More informationMonitoring Blood Pressure
Introduction Why monitor your blood pressure? Low blood pressure symptoms Hot to choose a monitor How to record your blood pressure General tips Twenty-four hour monitoring Helpful contacts Monitoring
More informationMonitoring Blood Pressure
Introduction Why monitor your own blood pressure? Low blood pressure symptoms How to choose a monitor How to record your blood pressure General tips Twenty-four hour monitoring Helpful contacts Monitoring
More informationClinical Guideline for the management of inpatients with Parkinson s disease
Clinical Guideline for the management of inpatients with Parkinson s disease Introduction: Parkinson s disease (PD) is the second most common neurodegenerative disorder, characterised by bradykinesia,
More informationAcute management of in-patient Parkinson s Disease patients
Acute management of in-patient Parkinson s Disease patients Contents Pages Introduction and Admission advice 2 Nil by Mouth Guidance 3 5 Complex therapy advice (Apomorphine, DBS, Duodopa) 6 Surgical peri-operative
More informationACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM
ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM 1 CONTENTS: TOPIC PAGE Introduction 3 What should you do when a PD
More informationAlso there may be some increased saliva production by the autonomic nervous system.
Introduction Possible problems What can be done? Too much saliva Too little saliva Thick saliva Further help Saliva Control Introduction This fact sheet is aimed at those affected by MSA and experiencing
More informationManagement of Parkinson s Disease in Primary and Secondary care for patients with compromised swallow or those patients deemed Nil By Mouth.
Management of Parkinson s Disease in Primary and Secondary care for patients with compromised swallow or those patients deemed Nil By Mouth. To aid the management and treatment of Parkinson s Patients
More informationScottish Medicines Consortium
Scottish Medicines Consortium rotigotine 2mg/24 hours, 4mg/24 hours, 6mg/24 hours, 8mg/24 hours transdermal patch (Neupro ) (No: 289/06) Schwarz Pharma Ltd. 7 July 2006 The Scottish Medicines Consortium
More informationParkinson's Disease and how you can make a difference with medication
Parkinson's Disease and how you can make a difference with medication Alyson Franks Parkinson's and Movement Disorder Nurse Specialist Royal Hallamshire Hospital No treatment all Complementary Therapy
More informationCommon medicines given to neurology patients on discharge from hospital
Common medicines given to neurology patients on discharge from hospital This leaflet contains brief information about some of the medicines we commonly supply on discharge to patients who have been admitted
More informationParkinson s Disease. Gillian Sare
Parkinson s Disease Gillian Sare Outline Reminder about PD Parkinson s disease in the inpatient Surgical patients with PD Patients who cannot swallow End of life care Parkinson s disease PD is the second
More informationThinking about advanced parkinson S
Thinking about advanced parkinson S Symptoms and lifestyle 1 This booklet looks at the advanced stage of Parkinson s. Advanced stage means a time when Parkinson s symptoms are more complex and may be having
More informationCommonly encountered medications and their side effects - what the generalist needs to know
Commonly encountered medications and their side effects - what the generalist needs to know Jeremy Cosgrove Consultant Neurologist Leeds Teaching Hospitals NHS Trust Outline: Parkinson s medications and
More informationCLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSON S DISEASE
CLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSON S DISEASE 1. Aim/Purpose of this Guideline To assist all doctors and nurses in the care of inpatients with Parkinson s disease. This guideline
More informationMotor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University
Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University I have no financial interest with any entity producing marketing, re-selling,
More informationGUIDELINES FOR THE MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE (PD) ADMITTED TO HOSPITAL. Reviewer s Name, Title & address:
GUIDELINES FOR THE MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE (PD) ADMITTED TO HOSPITAL Record Type Clinical Guideline elibrary ID Reference No: CG 1813 Newly developed and approved Trust-wide Clinical
More informationThe symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:
1 PARKINSON S DISEASE Parkinson's disease is a long term disease related to the central nervous system that mainly affects the motor system, resulting in the loss of dopamine, which helps in producing
More informationparts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to
parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug
More informationBest Medical Treatments for Parkinson s disease
Best Medical Treatments for Parkinson s disease Bernadette Schöneburg, M.D. June 20 th, 2015 What is Parkinson s Disease (PD)? Progressive neurologic disorder that results from the loss of specific cells
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August
BRAND NAME Xadago GENERIC NAME Safinamide MANUFACTURER Newron Pharmaceuticals SpA holds license; granted approval. US WorldMeds, LLC exclusive licensee and distributor in the U.S. DATE OF APPROVAL March
More informationNew Medicines Committee Briefing July 2011
New Medicines Committee Briefing July 2011 Pramipexole immediate-release (Mirapexin ) and Pramipexole modifiedrelease (Mirapexin prolonged release) for the treatment of Parkinson s Disease Pramipexole
More informationFinal Appraisal Report. ) for the treatment of idiopathic Parkinson s disease. Ropinirole prolonged-release (Requip XL. GlaxoSmithKline UK
Final Appraisal Report Ropinirole prolonged-release (Requip XL ) for the treatment of idiopathic Parkinson s disease GlaxoSmithKline UK Advice No: 1409 August 2009 Recommendation of AWMSG Ropinirole prolonged-release
More informationParkinson s Disease Prescribing Guidelines for use in Primary and Secondary Care
Parkinson's Disease Prescribing Guidelines for use in Primary and Secondary Care 2017 Parkinson s Disease Prescribing Guidelines for use in Primary and Secondary Care Document Description Document Type
More informationParkinson s Well-Being Map TM
Parkinson s Well-Being Map TM Supporting communication of my Parkinson s The Parkinson s Well-Being Map TM has been endorsed by: Developed in partnership with UCB. All rights reserved 0 UCB, Trademarks
More informationSummary of Patient < 3y at Visit 11 (90 months)
Summary of Patient < 3y at 11 (90 months) Clinician Scoring Page Direct online data entry available? Medication 378 Yes BPW 382 Yes Diagnostic Features 383 Yes UPDRS Clinician 388 Yes CISI-PD 397 Yes MoCA
More informationA Guide to Brain and Tissue Donation for Research
Introduction What is a Brain Bank? Why is research needed? Why do people donate? How to donate? Your questions answered Information on Brain Banks A Guide to Brain and Tissue Donation for Research Introduction
More informationLiving with Postural Hypotension
What is postural hypotension? What are the symptoms of postural hypotension? What to do when you get the symptoms When are the symptoms likely to happen? Can exercise help postural hypotension? Improving
More informationNHS Greater Glasgow And Clyde Pain Management Service. Information for Adult Patients who are Prescribed. Carbamazepine. For the Treatment of Pain
NHS Greater Glasgow And Clyde Pain Management Service Information for Adult Patients who are Prescribed Carbamazepine For the Treatment of Pain This information is not intended to replace your doctor s
More informationClinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: 05.16.17 Last Review Date: 08.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy
More informationA guide to Multiple System Atrophy for: General Practitioners
Introduction Prevalence Duration Initial presentation Red flags and symptoms Key management problems GP support The MSA Trust A guide to Multiple System Atrophy for: General Practitioners This document
More informationDrug treatments for Alzheimer s disease
Drug treatments for Alzheimer s disease Factsheet 407LP April 2018 There are no drug treatments that can cure Alzheimer s disease or any other common type of dementia. However, there are medicines for
More informationAnticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review:
More informationParkinson s Disease Medications: Professionals Edition
Parkinson s Disease Clinic and Research Center University of California, San Francisco 505 Parnassus Ave., Rm. 795-M, Box 0114 San Francisco, CA 94143-0114 (415) 476-9276 http://pdcenter.neurology.ucsf.edu
More informationHistory Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson
Parkinsonismm History Parkinson`s disease Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Definition : Parkinsonism: Parkinsonism is a progressive neurological
More informationMedicines Management and the Unwell Parkinson s Patient
Medicines Management and the Unwell Parkinson s Patient Belinda Kessel Geriatrician and Movement Disorder Specialist Princess Royal University Hospital Orpington, Kent The Society for Acute Medicine, 7
More informationMedicines in Scotland: What s the right treatment for me? Information for patients and the public
Medicines in Scotland: What s the right treatment for me? Information for patients and the public You can read and download this document from our website. We are happy to consider requests for other languages
More informationPatient information sheet: BuTrans Patch This information should be read in conjunction with the Taking Opioids for pain information leaflet
Page 1 of 6 Patient information sheet: BuTrans Patch This information should be read in conjunction with the Taking Opioids for pain information leaflet What type of drug is it? BuTrans transdermal patches
More informationCardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.
Cardinal Features of Parkinson s Management of Parkinson s Disease Kristin S. Meyer, PharmD, CGP, FASHP Assistant Professor of Pharmacy Practice Drake University & Iowa Veterans Home Spring 2009 Tremor
More informationWhy do I need to use Fentanyl Patches?
Why do I need to use Fentanyl Patches? Fentanyl patches are used to control on-going moderate to severe pain. They are not used for pain that only lasts for a short time. You will be given different, quick
More informationOptimizing Clinical Communication in Parkinson s Disease:
Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of
More informationObjectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.
Objectives Emerging Treatments in Parkinson s s Disease 1) Describe recent developments in the therapies for Parkinson s Disease Jeff Kraakevik MD Assistant Professor OHSU/Portland VAMC Parkinson s Center
More informationThe Fresco Institute for Parkinson's and Movement Disorders
The Fresco Institute for Parkinson's and Movement Disorders Follow Up Patient Questionnaire Name: Date: Accompanied by: Do you smoke? CURRENT PAST NEVER Which neurological symptom bothers you most right
More informationARE YOUR LEVODOPA PILLS WORKING LIKE THEY USED TO?
ARE YOUR LEVODOPA PILLS WORKING LIKE THEY USED TO? You may have noticed a change... Levodopa is a common treatment for Parkinson s, and doctors have relied on it for decades. Over time as Parkinson s progresses,
More informationOpioid Type Pain Killers
Opioid Type Pain Killers Information for patients, relatives and carers For more information, please contact: Palliative Care Team 01904 725835 (York) 01723 342446 (Scarborough) Renal Department 01904
More informationReQuip 0.25 mg, 1 mg, 2 mg, 5 mg film-coated tablets ropinirole (as the hydrochloride)
Package Leaflet: Information for the User ReQuip 0.25 mg, 1 mg, 2 mg, 5 mg film-coated tablets ropinirole (as the hydrochloride) Read all of this leaflet carefully before you start taking this medicine
More informationMedications used to treat Parkinson s disease
Medications used to treat Parkinson s disease Edwin B. George, M.D., Ph.D. Director of Wayne State University Movement Disorder Clinic University Health Center Neurology Clinic University Health The John
More informationNHS Greater Glasgow And Clyde Pain Management Service. Information for Adult Patients who are Prescribed. Pregabalin. For the Treatment of Pain
NHS Greater Glasgow And Clyde Pain Management Service Information for Adult Patients who are Prescribed Pregabalin For the Treatment of Pain This information is not intended to replace your doctor s advice.
More informationWhat s new for diagnosing and treating Parkinson s Disease?
What s new for diagnosing and treating Parkinson s Disease? Erika Driver-Dunckley, MD Associate Professor of Neurology Program Director Movement Disorders Fellowship Assistant Program Director Neurology
More informationHOW TO MANAGE MY SYMPTOMS & MEDICINES PARKINSON S PASSPORT. On time, every time with Parkinson s medicines. Endorsed by Australian College of Nursing
HOW TO MANAGE MY SYMPTOMS & MEDICINES PARKINSON S PASSPORT On time, every time with Parkinson s medicines Endorsed by Australian College of Nursing How to use your Parkinson s Passport Use the Parkinson
More informationAmitriptyline, Nortriptyline or Imipramine
NHS Greater Glasgow And Clyde Pain Management Service Information for Adult Patients who are Prescribed Amitriptyline, Nortriptyline or Imipramine For the Treatment of Pain This information is not intended
More informationNHS Greater Glasgow And Clyde Pain Management Service. Information for Adult Patients who are Prescribed. Duloxetine. For the Treatment of Pain
NHS Greater Glasgow And Clyde Pain Management Service Information for Adult Patients who are Prescribed Duloxetine For the Treatment of Pain This information is not intended to replace your doctor s advice.
More informationYour medicines for heart failure
Your medicines for heart failure This leaflet provides information about some of the medicines that you may be given to manage your heart failure. Always read the leaflet that comes with your medication
More informationContinence in MSA. How the bladder works
How the bladder works What goes wrong? What investigations need to be done? Who can help? Advice Medication Equipment Other help Useful contacts Continence in MSA Bladder problems are very common in people
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology
More informationIt is possible to manage the bladder problems of MSA even if they cannot be cured.
How the bladder works What goes wrong? What investigations need to be done? Who can help? Advice Medication Equipment Other help Useful contacts Continence in MSA It is possible to manage the bladder problems
More informationPatient guide to Capecitabine chemotherapy with radiotherapy for rectal cancer
Patient Name: Patient guide to chemotherapy with radiotherapy for rectal cancer Chemotherapy This guide should only be given to patients who have been prescribed capecitabine chemotherapy in conjunction
More informationA Review on Parkinson s Disease: Its Surgical Inventional Therapies, Pathophysiology and Treatment
Review Article A Review on Parkinson s Disease: Its Surgical Inventional Therapies, Pathophysiology and Treatment Himani Tiwari*, Pradeep K. Goyal, Chetan S. Chauhan, Yuveraj S. Sarangdevot Dept. of Quality
More informationIf you have dementia, you may have some or all of the following symptoms.
About Dementia Dementia may be caused by a number of illnesses that affect the brain. Dementia typically leads to memory loss, inability to do everyday things, difficulty in communication, confusion, frustration,
More informationKey Concepts and Issues in Parkinson s Disease in 2016
Key Concepts and Issues in Parkinson s Disease in 2016 Michael Rezak, M.D., Ph.D. Section Chief, Neurosciences Institute Director, Movement Disorders and Neurodegenerative Diseases Center Northwestern
More informationWeaning off requip. Cari untuk: Cari Cari
Cari untuk: Cari Cari Weaning off requip Weaning Off Mirapex. Readers have updated us on their weaning efforts. Mirapex has. I do not want to replace this med with Requip,. The pramipexole is the same
More informationWhere do you get most of your information about medications?
DRUG ACTION AND RLS Jacquelyn Bainbridge, Pharm.D., FCCP Professor Pei Shieen Wong, Pharm.D., BCPS University of Colorado Anschutz Medical Campus, Skaggs School of Pharmacy and Pharmaceutical Sciences,
More informationTreatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS
Treatment of Parkinson s Disease and of Spasticity Satpal Singh Pharmacology and Toxicology 3223 JSMBS singhs@buffalo.edu 716-829-2453 1 Disclosures NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS
More informationProgram Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York
Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone
More informationManaging your pain at home after surgery. Information for patients
Managing your pain at home after surgery Information for patients Managing your pain at home after surgery This leaflet has been written in order to give you some advice regarding your pain management
More informationParkinson s Disease Current Treatment Options
Parkinson s Disease Current Treatment Options Daniel Kassicieh, D.O., FAAN Sarasota Neurology, P.A. PD: A Chronic Neurodegenerative Ds. 1 Million in USA Epidemiology 50,000 New Cases per Year Majority
More informationA Review on Parkinson s Disease: Its Pathophysiology, Treatment and Surgery
25 Review Article A Review on Parkinson s Disease: Its Pathophysiology, Treatment and Surgery Singh Divya 1, Siddhi Shrimali 2, Rathore KS 2 * 1 Department of Pharmacology, Jaipur College of Pharmacy,
More informationGuideline for the Management of Parkinson s Disease Medication Trust Reference B26/2017
Guideline for the Management of Parkinson s Disease Medication Trust Reference B26/2017 1. INTRUCTION 1.1 Guideline for the management of Parkinson s Disease Medication in adult patients presenting to
More informationMedicines to treat pain in adults. Information for patients and carers
Medicines to treat pain in adults Information for patients and carers It is common to feel some pain after having an operation (surgery), trauma or an infection. Controlling pain is an important part of
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning
More informationDorset Medicines Advisory Group SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE
SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE INDICATION By inhibiting metabolism of levodopa, entacapone or opicapone allow a reduction
More informationRe-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.
Scottish Medicines Consortium Re-Submission rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd 10 November 2006 The Scottish Medicines Consortium (SMC) has completed
More informationSlow Release Opioids. Morphine (Zomorph/MST) Oxycodone (Longtec, Oxycontin) Tapentadol (Palexia) For the Treatment of Pain
NHS Greater Glasgow And Clyde Pain Management Service Information for Adult Patients who are Prescribed Slow Release Opioids Morphine (Zomorph/MST) Oxycodone (Longtec, Oxycontin) Tapentadol (Palexia) For
More informationCommunicating About OFF Episodes With Your Doctor
Communicating About OFF Episodes With Your Doctor Early in Parkinson s disease (PD), treatment with levodopa and other anti-pd drugs provides continuous benefit. As the disease progresses, however, symptom
More informationSofosbuvir, Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C
Sofosbuvir, Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Department of Hepatology Digestive Diseases Centre Patient Information This leaflet is designed to give you important information
More informationUnderstanding Parkinson s Disease Important information for you and your loved ones
Patient Education Understanding Parkinson s Disease Important information for you and your loved ones This handout explains the signs, symptoms, and possible treatments of Parkinson s disease. Parkinson
More informationSection 1: What is Parkinson s? Parkinson's Disease Webinar 4/27/2012. April 27th, :00-1:00 PM EST
4/27/2012 Parkinson's Disease Webinar April 27th, 2012 12:00-1:00 PM EST Presenter: Jon Collins, Manager, Programs and Events, Parkinson Society Central & Northern Ontario Section 1: What is Parkinson
More informationDrugs for Parkinson s Disease
This Clinical Resource gives subscribers additional insight related to the Recommendations published in July 2017 ~ Resource #330705 Drugs for Parkinson s Disease Parkinson s disease is characterized by
More informationCENTRE FOR PHARMACY POSTGRADUATE EDUCATION. Parkinson s disease. Book2. A CPPE focal point programme
CENTRE FOR PHARMACY POSTGRADUATE EDUCATION Parkinson s disease A CPPE focal point programme Book2 FP126/2 September 2015 Parkinson s disease Book 2 Content contributors Caroline Barraclough, regional manager,
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
ZELAPAR (selegiline hydrochloride) orally disintegrating tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationDrug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually
More informationREFERENCE CODE GDHC235CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - US DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC235CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - US DRUG FORECAST AND MARKET ANALYSIS TO 2022 Sales for Parkinson s Disease in the US The Parkinson s disease market in the
More informationParkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.
Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O. Parkinson s Epidemiology AFFECTS 1% OF POPULATION OVER 65 MEAN AGE OF ONSET 65 MEN:WOMEN 1.5:1 IDIOPATHIC:HEREDITARY 90:10
More informationMEDICATION GUIDE DUOPA (Do-oh-pa) (carbidopa and levodopa) enteral suspension
MEDICATION GUIDE DUOPA (Do-oh-pa) (carbidopa and levodopa) enteral suspension Read this Medication Guide before you start using DUOPA and each time you get a refill. There may be new information. This
More informationDESCRIPTION.
Tapering off requip May 29, 2015. We conclude that for augmentation in RLS, gradual tapering of the there were four patients taking regular or extended length ropinirole with a mean. Of the 7 patients
More information[SIMIPEX XR] modified release tablets
[SIMIPEX XR] modified release tablets Pramipexole hydrochloride monohydrate Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about SIMIPEX XR. It does not
More informationOral N-Acetyl CystieneTablets. Patient Information
Oral N-Acetyl CystieneTablets Patient Information Author ID: AA Leaflet Number: Resp 001 Version: 4 Name of Leaflet: Oral N-Acetyl Cystiene Tablets Date Produced: August 2017 Review Date: August 2019 N-acetyl
More informationDisclosures. Objectives. What s Shaking? Tremors and Movement Disorders
Disclosures What s Shaking? Tremors and Movement Disorders Jill L. Ostrem, MD Associate Professor of Neurology Surgical Movement Disorders Center Consultant and speaker: Allergan Inc., Medtronic Inc.,
More informationControlling nausea and vomiting: anti-emetic therapy advice
Controlling nausea and vomiting: anti-emetic therapy advice Chemotherapy A guide for patients and carers Contents Treatments that may cause nausea and vomiting... 2 Physical reasons that may cause nausea
More informationPain Management after Discharge from Hospital
Pain Management after Discharge from Hospital South Tyneside Anaesthetics Department and Acute Pain Services 1 Part of: South Tyneside and Sunderland Healthcare Group 2 Information for patients This leaflet
More informationPACKAGE LEAFLET. Page 1 of 6
PACKAGE LEAFLET Page 1 of 6 Package leaflet: Information for the patient Procyclidine Hydrochloride 5 mg Tablets (procyclidine hydrochloride) Read all of this leaflet carefully before you start taking
More informationManagement of Neurological Conditions at End of Life
Management of Neurological Conditions at End of Life Erwin B. Montgomery Jr. MD Professor of Neurology McMaster University, Hamilton ON Medical Director Greenville Neuromodulation Center, Greenville PA
More informationPatient Action Plan Patient Action Plan
1 of 8 Congratulations! You ve taken a positive first step by talking with your doctor about your symptoms of depression. No doubt you re committed to getting the most out of depression treatment by communicating
More informationPackage Leaflet: Information for the user Kemadrin 5 mg Tablets Procyclidine hydrochloride
Package Leaflet: Information for the user Kemadrin 5 mg Tablets Procyclidine hydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important information
More information